Press Release

Printer Friendly VersionView printer-friendly version << Back

Protagonist Therapeutics Announces Acceptance of Late Breaking Abstract for PTG-100 at the United European Gastroenterology Week Meeting

NEWARK, Calif., Oct. 8, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dr. William J. Sandborn will present clinical data from a Phase 2 study of PTG-100, the Company's oral, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide that is being developed for treatment of ulcerative colitis, at the United European Gastroenterology Week meeting. The data will be presented on Monday, October 22 at 14:00 CEST in Vienna, Austria and will be published in the December issue of European Gastroenterology Journal.

Protagonist Therapeutics, Inc. (PRNewsFoto/Protagonist Therapeutics, Inc.)

Presentation details:

Presentation Title: PTG-100, an oral gut-restricted peptide alpha-4-beta-7 antagonist induces clinical and histologic remission in patients with moderate to severely active ulcerative colitis
Date and Time: Monday, October 22 from 14:00 to 15:30 CEST
Session: Room C – Clinical trials in IBD
Location: ACV, Vienna, Austria

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-100 is an oral alpha-4-beta-7 integrin specific antagonist peptide that is under development for potential treatment of inflammatory bowel diseases. PTG-200 is an oral peptide interleukin-23 receptor antagonist in development for the treatment of Crohn's disease. The company has entered into a worldwide license and collaboration agreement with Janssen Biotech for the clinical development of PTG-200. Protagonist is also developing an injectable hepcidin mimetic, PTG-300, for the potential treatment of anemia and iron overload related to rare blood diseases with an initial focus on beta-thalassemia. The company has completed a Phase 1 clinical trial of PTG-300, which established safety/tolerability and pharmacodynamic-based clinical proof-of-concept in normal healthy volunteers. The U.S. Food and Drug Administration has granted Orphan Drug designation and Fast Track designation to PTG-300 for beta-thalassemia for which a global Phase 2 trial is to be initiated in the fourth quarter of 2018.

Protagonist is headquartered in Newark, California, with pre-clinical and clinical staff in California and discovery operations in both California and Brisbane, Queensland, Australia. For further information, please visit


Cision View original content to download multimedia:

SOURCE Protagonist Therapeutics, Inc.

Solebury Trout, Rich Allan (media), Tel: +1 646-378-2958, Email:; Marcy Nanus (investors), Tel: +1 646-378-2927, Email: